TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Industry News Articles > Signal detection – the complete guide

Signal detection – the complete guide

WHAT IS A SIGNAL

A signal can be an increase in frequency/severity/specificity of a labelled event or a new unlabelled adverse event or a newly identified drug-drug/drug-food/drug-alcohol interactions or a medication error/product issue or identification of a new population at risk or a new beneficial effect of a drug
Information that arises from one or multiple sources (including observations and experiments), which suggests a new potentially causal association, or a new aspect of a known association, between an intervention and an event or set of related events, either adverse or beneficial, that is judged to be of sufficient likelihood to justify verificatory action. (CIOMS VIII – Practical Aspects of Signal Detection in Pharmacovigilance)
A concern about an excess of adverse events compared to what would be expected to be associated with a product’s use. (FDA)
Reported information on a possible causal relationship between an adverse event and a drug, the relationship being unknown or incompletely documented previously. (WHO)

What is a Signal

A signal suggests a possible causal association between the drug and the adverse event.

WHY DO WE NEED TO PERFORM SIGNAL DETECTION?
Any new medicinal product prior to getting a marketing approval from any regulatory authority would have to show positive benefit-risk ratio (i.e., the anticipated benefits for the intended indication should outweigh the risks or harmful effects from the use of the medicinal product/intervention). The information on this benefit-risk is reached at, through years of experimenting and researching in the laboratories, animals, and humans through pre-clinical and clinical studies (Phase I-IV). At the time of marketing approval, the product would have shown positive benefit-risk ratio based on the human exposure in the clinical trials (often limited to a few thousand).
The limited exposure in the clinical trials and with exclusion criteria’s (primarily excluding paediatric, elderly, pregnant & lactating woman, renal & hepatic impaired, medical histories, etc.), lack of long-term treatment effect, and limited concomitant medication exposure, the clinical trials do not reach the power to identify all the adverse reactions (rare/very rare) possible with a drug. Hence, there is limited information on the safety & efficacy of a medicinal product at the time of receiving marketing approval
To ensure the benefit-risk ratio of a product always stays positive, the Marketing authorisation holders (MAHs) are expected to perform continuous reviews of all the possible sources to identify new safety information related to a product. The knowledge on the drug’s safety profile, pharmacological actions, rare adverse events, and clinical effectiveness increases over the years following approval. This is usually achieved by active surveillance by expedited reporting, periodic reports, and signal detection activities with mutual exchange of safety data with the regulators. Hence, we perform signal detection.

WHAT ARE THE SOURCES OF SIGNALS
A signal can arise from multiple sources as depicted in the figure below.

Signal Sources

WHAT ARE THE CHALLENGES IN SIGNAL DETECTION?
The road to detecting, validating and confirming signals is usually filled with potholes making the journey of identifying, evaluating and establishing a signal/risk, sometimes very challenging.

  • Limited information on the background incidence of the event in the untreated general population
  • Lack of information on the frequency of the events in the drug exposed population (considering the deficiencies in the reported cases/events)
  • The reporting frequency and the number of reported cases is less for drugs with less exposure
  • Limited information on the temporal association, dose-effect, medical history, co-morbid conditions, and concomitant medications
  • Effects of long-term exposure or effects in the long-term following exposure (e.g. Exposure to diethylsilbesterol [DES] in pregnant women and development of vaginal carcinoma in their daughters)

HOW DOES PHARMALEX HELP OVERCOME THESE CHALLENGES
Our team of experts are well versed and experienced in evaluating and critically appraising ICSRs, aggregate data, and literature and thereby providing a comprehensive evaluation report considering the strengths and weaknesses of all the data sets and sources reviewed.
Where data on a safety issue is limited, our experts customize a search strategy which is not only specific but also sensitive which addresses the medical topic.
As needed, our safety experts liaise with our toxicology experts in critically appraising and evaluating the pre-clinical and toxicology data to compliment and to provide a comprehensive evaluation of the safety issue.

Contact us
Related posts
Why collaboration and an Integrated Product Development program are key to successful drug development
Why collaboration and an Integrated Product Development program are key to successful drug development
14th June 2022
Key Takeaways from the PDA Europe Annex 1 Workshop
Key Takeaways from the PDA Europe Annex 1 Workshop
7th June 2022
NLS DAYS 2022
NLS DAYS 2022
September 28 - May 29th, 2022
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Search
Upcoming Webinars

June 28th, 2022

eCTD in Australia: key steps to start a successful submission

08:30 am CET / 4:30 pm AEST

June 28th, 2022

An Introduction to Bayesian adaptive methods in clinical trials

04:00 PM CET

June 30th, 2022

Transforming the drug development process with an integrated strategy

03:00 PM CET

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
24 Jun

Milena Shuytsova-Mircheva and Lisa Pascoe latest blog here https://www.pharmalex.com/sponsors-gear-up-for-a-smoother-process-with-ctis-but-must-first-overcome-key-hurdles/ discusses the benefit of the Clinical Trial Information System (CTIS).

💡 Interested in CTIS? Take the Phlexglobal survey to evaluate your preparation https://www.phlexglobal.com/ctis-survey

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • We couldn’t have asked for a more professional, personable, knowledgeable group of Quality Experts!

    Top 10 Pharma Company, China
    Drug Safety Director
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for